Sharechat Logo

Ebos reports higher profit, looks for acquisitions

NZPA

Friday 26th August 2011

Text too small?

Medical equipment company Ebos Group has reported an 19 percent rise in profit from continuing operations achieved in what it describes as an outstanding year.

The company is looking at acquisitions and is optimistic about its position in a range of markets in the health sector.

Ebos reported a net profit from continuing operations of $23.4 million in the year to June 30, 2011, up from $19.69 million in the same period a year ago.

Net profit after tax of $31.58m was up from $23.44m. Revenue rose to $1.34 billion from $1.32 billion.

Directors declared a final dividend of 18 cents a share payable on October 7.

"In the past four years since we expanded our interests in pharmaceutical wholesaling and logistics, earnings have more than doubled," the company said.

The company said the increase in sales was achieved even though three devastating earthquakes in Canterbury, New Zealand, and disastrous flooding in eastern Australia had an impact on discretionary healthcare spending.

The group was able to maintain the supply of crucial pharmaceutical and medical supplies on time to key public healthcare customers with minimal disruption to the supply chain.



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Daily ShareChat: EBOS Group